Diana Charlson
Family · Sheridan, WYNPI 1689129116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $796, 4.4 times the $182 reported in 2021.
Across 106 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$316
- AstraZeneca$310
- Lilly USA, LLC$236
- Amgen$174
- AbbVie$129
- Madrigal Pharmaceuticals$120
- plus $611 from 17 others
What the payments were for
- Food & beverage$1,87599%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 17 | $316 |
| AstraZeneca | 19 | $310 |
| Lilly USA, LLC | 22 | $236 |
| Amgen | 11 | $174 |
| AbbVie | 6 | $129 |
| Madrigal Pharmaceuticals | 1 | $120 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $80 |
| Novo Nordisk | 5 | $75 |
| Insulet Corporation | 1 | $72 |
| Edwards Lifesciences | 2 | $60 |
| Astellas Pharma US Inc | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Novartis | 2 | $32 |
| Eisai Inc. | 2 | $29 |
| Alkermes, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Medtronic | 1 | $23 |
| Abbott | 1 | $22 |
| Corium, LLC | 1 | $21 |
| Exact Sciences | 1 | $15 |
| Merck | 1 | $14 |
| Bayer | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$120
How this compares
$1,896 in reported general payments places this provider in the 85th percentile of 284 family providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $108,332 |
| OzempicSemaglutide | 84 | $97,079 |
| FarxigaDapagliflozin Propanediol | 72 | $81,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $42,096 |
| JardianceEmpagliflozin | 32 | $37,764 |
| RybelsusSemaglutide | 28 | $32,174 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $28,076 |
| XareltoRivaroxaban | 15 | $21,121 |
| JanuviaSitagliptin Phosphate | 12 | $18,232 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $17,899 |
| TrulicityDulaglutide | 16 | $15,508 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $14,548 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $13,640 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $12,013 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $75 | $129,253112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $310 | $90,98488 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $316 | $90,376124 claims |
| MerckJanuvia | $14 | $18,23212 claims |
| Lilly USA, LLCTrulicity | $236 | $15,50816 claims |
| AbbVieSynthroid | $129 | $2,25236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 284 family providers in Wyoming.
Other family in Sheridan
- Amanda McIntireSheridan$4K
- Rebekah MontgomerySheridan$3K
- Jeffrey ShidemanSheridan$2K
- Wendy Wood NeesonSheridan$1K
- Jill GiranyCheyenne$44K
- Brenna KirschGillette$14K
- Debra GrinerCasper$9K
- Kelly EckesCasper$7K
- Jamie MosbruckerCasper$6K
- Kathryn HeimerCheyenne$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.